Media headlines about Aegerion Pharmaceuticals (NASDAQ:AEGR) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Aegerion Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 43.8400465061349 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Aegerion Pharmaceuticals (AEGR) remained flat at $$1.97 during mid-day trading on Tuesday. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of -19.22. Aegerion Pharmaceuticals has a twelve month low of $1.23 and a twelve month high of $10.85. The firm has a market cap of $56.69, a price-to-earnings ratio of -0.33 and a beta of 0.50.
TRADEMARK VIOLATION NOTICE: This news story was originally published by BBNS and is the property of of BBNS. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-aegerion-pharmaceuticals-aegr-share-price/1820809.html.
Aegerion Pharmaceuticals, Inc is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor.
Receive News & Ratings for Aegerion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aegerion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.